XLO
Xilio Therapeutics, Inc.
+0.02 (+0.22%)9.00USD2.6K成交股數52.0M市值–本益比(近四季)0.8股價營收比+131.2%營收年增(近四季)–下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 44K · 0.00 |
| 近 180 天 淨額 | 44K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-26 | 03-30 | Shannon James Samuel | Director | P 公開市場買進 | 5.0K | 8.79 | 44K | 10.0K | SEC |
| 2026-01-02 | 01-05 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | S 公開市場賣出(10b5-1) | 1.8K | 0.64 | 1K | 6.4K | SEC |
| 2026-01-02 | 01-05 | Frankenfield Christopher James | Chief Financial Officer | S 公開市場賣出(10b5-1) | 7.0K | 0.64 | 4K | 24.8K | SEC |
| 2026-01-01 | 01-05 | Luptakova Katarina | CHIEF MEDICAL OFFICER | M 選擇權執行 | 16.6K | – | – | 33.3K | SEC |
| 2026-01-01 | 01-05 | Russo Rene | PRESIDENT AND CEO | M 選擇權執行 | 44.3K | – | – | 325K | SEC |
| 2026-01-01 | 01-05 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M 選擇權執行 | 5.0K | – | – | 8.2K | SEC |
| 2026-01-01 | 01-05 | Frankenfield Christopher James | Chief Financial Officer | M 選擇權執行 | 19.4K | – | – | 31.8K | SEC |
| 2025-06-17 | 06-18 | Shannon James Samuel | Director | P 公開市場買進 | 25.0K | 0.69 | 17K | 70.0K | SEC |
| 2025-06-16 | 06-18 | Russo Rene | PRESIDENT AND CEO | P 公開市場買進 | 36.3K | 0.68 | 25K | 281K | SEC |
| 2025-06-16 | 06-18 | Shannon James Samuel | Director | P 公開市場買進 | 45.0K | 0.69 | 31K | 45.0K | SEC |
| 2025-01-02 | 01-03 | Frankenfield Christopher James | Chief Financial Officer | S 公開市場賣出(10b5-1) | 7.0K | 0.98 | 7K | 12.4K | SEC |
| 2025-01-02 | 01-03 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | S 公開市場賣出(10b5-1) | 1.8K | 0.98 | 2K | 3.2K | SEC |
| 2025-01-01 | 01-03 | Russo Rene | PRESIDENT AND CEO | M 選擇權執行 | 44.3K | – | – | 245K | SEC |
| 2025-01-01 | 01-03 | Luptakova Katarina | CHIEF MEDICAL OFFICER | M 選擇權執行 | 16.6K | – | – | 16.6K | SEC |
| 2025-01-01 | 01-03 | Frankenfield Christopher James | Chief Financial Officer | M 選擇權執行 | 19.4K | – | – | 19.4K | SEC |
| 2025-01-01 | 01-03 | Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M 選擇權執行 | 5.0K | – | – | 5.0K | SEC |
| 2024-12-18 | 12-19 | GILEAD SCIENCES, INC. | TenPercentOwner | P 公開市場買進 | 1.8M | 1.04 | 1.8M | 9.1M | SEC |
| 2024-04-02 | 04-03 | GILEAD SCIENCES, INC. | TenPercentOwner | P 公開市場買進 | 485K | 0.76 | 369K | 7.3M | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Fund XI, L.P. | TenPercentOwner | S 公開市場賣出 | 733 | 0.64 | 469.12 | 2.0M | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Fund XI, L.P. | TenPercentOwner | S 公開市場賣出 | 267 | 0.64 | 170.88 | 735K | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | S 公開市場賣出 | 733 | 0.64 | 469.12 | 2.0M | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | S 公開市場賣出 | 267 | 0.64 | 170.88 | 735K | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | S 公開市場賣出 | 733 | 0.64 | 469.12 | 2.0M | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | S 公開市場賣出 | 267 | 0.64 | 170.88 | 735K | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates Opportunity I, LLC | TenPercentOwner | S 公開市場賣出 | 733 | 0.64 | 469.12 | 2.0M | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates Opportunity I, LLC | TenPercentOwner | S 公開市場賣出 | 267 | 0.64 | 170.88 | 735K | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates XI, LLC | TenPercentOwner | S 公開市場賣出 | 733 | 0.64 | 469.12 | 2.0M | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates XI, LLC | TenPercentOwner | S 公開市場賣出 | 267 | 0.64 | 170.88 | 735K | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates XI, L.P. | TenPercentOwner | S 公開市場賣出 | 733 | 0.64 | 469.12 | 2.0M | SEC |
| 2024-02-08 | 02-09 | Atlas Venture Associates XI, L.P. | TenPercentOwner | S 公開市場賣出 | 267 | 0.64 | 170.88 | 735K | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates XI, L.P. | TenPercentOwner | S 公開市場賣出 | 560 | 0.83 | 464.80 | 735K | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Fund XI, L.P. | TenPercentOwner | S 公開市場賣出 | 1.5K | 0.83 | 1K | 2.0M | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Fund XI, L.P. | TenPercentOwner | S 公開市場賣出 | 560 | 0.83 | 464.80 | 735K | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | S 公開市場賣出 | 1.5K | 0.83 | 1K | 2.0M | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | S 公開市場賣出 | 560 | 0.83 | 464.80 | 735K | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | S 公開市場賣出 | 1.5K | 0.83 | 1K | 2.0M | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | S 公開市場賣出 | 560 | 0.83 | 464.80 | 735K | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates Opportunity I, LLC | TenPercentOwner | S 公開市場賣出 | 1.5K | 0.83 | 1K | 2.0M | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates Opportunity I, LLC | TenPercentOwner | S 公開市場賣出 | 560 | 0.83 | 464.80 | 735K | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates XI, LLC | TenPercentOwner | S 公開市場賣出 | 1.5K | 0.83 | 1K | 2.0M | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates XI, LLC | TenPercentOwner | S 公開市場賣出 | 560 | 0.83 | 464.80 | 735K | SEC |
| 2024-01-12 | 01-16 | Atlas Venture Associates XI, L.P. | TenPercentOwner | S 公開市場賣出 | 1.5K | 0.83 | 1K | 2.0M | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Fund XI, L.P. | TenPercentOwner | S 公開市場賣出 | 1.6K | 0.87 | 1K | 2.0M | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | S 公開市場賣出 | 569 | 0.87 | 495.03 | 735K | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates XI, LLC | TenPercentOwner | S 公開市場賣出 | 569 | 0.87 | 495.03 | 735K | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates Opportunity I, LLC | TenPercentOwner | S 公開市場賣出 | 1.6K | 0.87 | 1K | 2.0M | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | S 公開市場賣出 | 569 | 0.87 | 495.03 | 735K | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Opportunity Fund I, L.P. | TenPercentOwner | S 公開市場賣出 | 1.6K | 0.87 | 1K | 2.0M | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates Opportunity I, LLC | TenPercentOwner | S 公開市場賣出 | 569 | 0.87 | 495.03 | 735K | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Fund XI, L.P. | TenPercentOwner | S 公開市場賣出 | 569 | 0.87 | 495.03 | 735K | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates XI, L.P. | TenPercentOwner | S 公開市場賣出 | 1.6K | 0.87 | 1K | 2.0M | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates XI, L.P. | TenPercentOwner | S 公開市場賣出 | 569 | 0.87 | 495.03 | 735K | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates Opportunity I, L.P. | TenPercentOwner | S 公開市場賣出 | 1.6K | 0.87 | 1K | 2.0M | SEC |
| 2024-01-11 | 01-16 | Atlas Venture Associates XI, LLC | TenPercentOwner | S 公開市場賣出 | 1.6K | 0.87 | 1K | 2.0M | SEC |
| 2021-12-10 | 12-10 | BCIP Life Sciences Associates, LP | TenPercentOwner | P 公開市場買進 | 3.2K | 10.24 | 33K | 2.8M | SEC |
| 2021-12-10 | 12-10 | Bain Capital Life Sciences Investors II, LLC | TenPercentOwner | P 公開市場買進 | 21.8K | 9.56 | 209K | 2.8M | SEC |
| 2021-12-10 | 12-10 | Bain Capital Life Sciences Investors II, LLC | TenPercentOwner | P 公開市場買進 | 3.2K | 10.24 | 33K | 2.8M | SEC |
| 2021-12-10 | 12-10 | BCLS II Investco, LP | TenPercentOwner | P 公開市場買進 | 3.2K | 10.24 | 33K | 2.8M | SEC |
| 2021-12-10 | 12-10 | BCLS II Investco, LP | TenPercentOwner | P 公開市場買進 | 21.8K | 9.56 | 209K | 2.8M | SEC |
| 2021-12-10 | 12-10 | BCIP Life Sciences Associates, LP | TenPercentOwner | P 公開市場買進 | 21.8K | 9.56 | 209K | 2.8M | SEC |
| 2021-12-10 | 12-10 | BCLS II Investo (GP), LLC | TenPercentOwner | P 公開市場買進 | 3.2K | 10.24 | 33K | 2.8M | SEC |
| 2021-12-10 | 12-10 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | P 公開市場買進 | 21.8K | 9.56 | 209K | 2.8M | SEC |
| 2021-12-10 | 12-10 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | P 公開市場買進 | 3.2K | 10.24 | 33K | 2.8M | SEC |
| 2021-12-10 | 12-10 | BCLS II Investo (GP), LLC | TenPercentOwner | P 公開市場買進 | 21.8K | 9.56 | 209K | 2.8M | SEC |
| 2021-12-10 | 12-10 | Bain Capital Life Sciences Fund II, L.P. | TenPercentOwner | P 公開市場買進 | 21.8K | 9.56 | 209K | 2.8M | SEC |
| 2021-12-10 | 12-10 | Bain Capital Life Sciences Fund II, L.P. | TenPercentOwner | P 公開市場買進 | 3.2K | 10.24 | 33K | 2.8M | SEC |
| 2021-12-09 | 12-10 | Bain Capital Life Sciences Fund II, L.P. | TenPercentOwner | P 公開市場買進 | 4.0K | 9.84 | 39K | 2.8M | SEC |
| 2021-12-09 | 12-10 | BCLS II Investo (GP), LLC | TenPercentOwner | P 公開市場買進 | 4.0K | 9.84 | 39K | 2.8M | SEC |
| 2021-12-09 | 12-10 | BCLS II Investco, LP | TenPercentOwner | P 公開市場買進 | 4.0K | 9.84 | 39K | 2.8M | SEC |
| 2021-12-09 | 12-10 | Bain Capital Life Sciences Investors II, LLC | TenPercentOwner | P 公開市場買進 | 4.0K | 9.84 | 39K | 2.8M | SEC |
| 2021-12-09 | 12-10 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | P 公開市場買進 | 4.0K | 9.84 | 39K | 2.8M | SEC |
| 2021-12-09 | 12-10 | BCIP Life Sciences Associates, LP | TenPercentOwner | P 公開市場買進 | 4.0K | 9.84 | 39K | 2.8M | SEC |
| 2021-12-08 | 12-10 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | P 公開市場買進 | 13.5K | 9.62 | 129K | 2.8M | SEC |
| 2021-12-08 | 12-10 | BCIP Life Sciences Associates, LP | TenPercentOwner | P 公開市場買進 | 13.5K | 9.62 | 129K | 2.8M | SEC |
| 2021-12-08 | 12-10 | Bain Capital Life Sciences Fund II, L.P. | TenPercentOwner | P 公開市場買進 | 13.5K | 9.62 | 129K | 2.8M | SEC |
| 2021-12-08 | 12-10 | Bain Capital Life Sciences Investors II, LLC | TenPercentOwner | P 公開市場買進 | 13.5K | 9.62 | 129K | 2.8M | SEC |
| 2021-12-08 | 12-10 | BCLS II Investco, LP | TenPercentOwner | P 公開市場買進 | 13.5K | 9.62 | 129K | 2.8M | SEC |
| 2021-12-08 | 12-10 | BCLS II Investo (GP), LLC | TenPercentOwner | P 公開市場買進 | 13.5K | 9.62 | 129K | 2.8M | SEC |
| 2021-10-26 | 11-03 | SV7 Impact Medicine Fund LP | TenPercentOwner | C 轉換 | 999K | – | – | 999K | SEC |
| 2021-10-26 | 11-03 | SV7 Impact Medicine Fund LP | TenPercentOwner | C 轉換 | 999K | – | – | 999K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664K | 6.4M | 新進 | 新進 |
| ORBIMED ADVISORS LLC | 592K | 5.7M | 新進 | 新進 |
| Frazier Life Sciences Management, L.P. | 423K | 4.0M | 新進 | 新進 |
| Stonepine Capital Management, LLC | 226K | 2.2M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 179K | 1.7M | 新進 | 新進 |
| Sio Capital Management, LLC | 152K | 1.5M | 新進 | 新進 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 112K | 1.1M | 新進 | 新進 |
| Merck & Co., Inc. | 106K | 1.0M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 64.2K | 615K | 新進 | 新進 |
| MORGAN STANLEY | 57.0K | 546K | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 39.1K | 374K | 新進 | 新進 |
| 城堡 CITADEL ADVISORS LLC | 25.9K | 249K | 新進 | 新進 |
| VANGUARD FIDUCIARY TRUST CO | 22.6K | 216K | 新進 | 新進 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 17.5K | 168K | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 14.5K | 139K | 新進 | 新進 |
| Velan Capital Investment Management LP | 14.3K | 137K | 新進 | 新進 |
| STATE STREET CORP | 13.3K | 128K | 新進 | 新進 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 11.6K | 111K | 新進 | 新進 |
| BlackRock, Inc. | 8.8K | 84K | 新進 | 新進 |
| Steward Partners Investment Advisory, LLC | 714 | 7K | 新進 | 新進 |
| BARCLAYS PLC | 115 | 1K | 新進 | 新進 |
| Key Financial Inc | 59 | 565.00 | 新進 | 新進 |
| JONES FINANCIAL COMPANIES LLLP | 29 | 262.00 | 新進 | 新進 |
| UBS Group AG | 14 | 134.00 | 新進 | 新進 |
| GSA CAPITAL PARTNERS LLP | 13.6K | 130.00 | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 25 +2 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 25 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 2.8M · 47.7% |
| 合計季末市值 | 26.3M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 418K |
|---|---|
| 與上期比 | -0.9% |
| 佔流通股數 | 7.23% |
| 日均成交量 | 10.7K |
| 回補天數 | 39.1 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 418K | -0.9% | 7.23% | 10.7K | 39.1 |
| 2026-08-14 | 422K | -0.9% | 7.30% | 13.3K | 31.6 |
| 2026-07-31 | 426K | +58.8% | 7.37% | 34.7K | 12.3 |
| 2026-07-15 | 268K | +53.6% | 4.64% | 59.3K | 4.5 |
| 2026-06-30 | 175K | +0.7% | 3.02% | 47.9K | 3.7 |
| 2026-06-15 | 173K | +5.0% | 3.00% | 24.5K | 7.1 |
| 2026-05-29 | 165K | -3.6% | 2.86% | 30.5K | 5.4 |
| 2026-05-15 | 171K | +5.2% | 2.96% | 95.0K | 1.8 |
| 2026-04-30 | 163K | -6.5% | 2.82% | 33.0K | 4.9 |
| 2026-04-15 | 174K | -4.5% | 3.01% | 29.4K | 5.9 |
| 2026-03-31 | 182K | -91.8% | 3.16% | 58.3K | 3.1 |
| 2026-03-13 | 2.2M | +5.6% | 38.59% | 481K | 4.6 |
| 2026-02-27 | 2.1M | -1.9% | 36.55% | 312K | 6.8 |
| 2026-02-13 | 2.2M | +0.8% | 37.28% | 602K | 3.6 |
| 2026-01-30 | 2.1M | +2.4% | 37.00% | 516K | 4.1 |
| 2026-01-15 | 2.1M | -3.7% | 36.12% | 358K | 5.8 |
| 2025-12-31 | 2.2M | -29.8% | 37.50% | 270K | 8.0 |
| 2025-12-15 | 3.1M | -53.7% | 53.41% | 737K | 4.2 |
| 2025-11-28 | 6.7M | -3.4% | 115.45% | 372K | 17.9 |
| 2025-11-14 | 6.9M | +12.3% | 119.55% | 1.2M | 5.9 |
| 2025-10-31 | 6.2M | +17.2% | 106.46% | 718K | 8.6 |
| 2025-10-15 | 5.3M | +1.7% | 90.82% | 423K | 12.4 |
| 2025-09-30 | 5.2M | +4.8% | 89.28% | 387K | 13.3 |
| 2025-09-15 | 4.9M | +14.5% | 85.15% | 1.5M | 3.4 |
| 2025-08-29 | 4.3M | -0.2% | 74.38% | 396K | 10.9 |
| 2025-08-15 | 4.3M | +12.7% | 74.51% | 452K | 9.5 |